




PCT/IB04/01350



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




BEST AVAILABLE COPY
BEST AVAILABLE COPY

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 17 February 2004


**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977
Rule 16)

The
Patent
Office

1/77



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

1. Your Reference

MM/PB60162P

2. Patent application number

(The Patent office will fill in this part)

09 APR 2003

0308208.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LIMITED
GLAXO WELLCOME HOUSE
BERKELEY AVENUE
GREENFORD
MIDDLESEX
UB6 0NN
GB

00473587003

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

CHEMICAL COMPOUNDS

4 Title of the invention

MICHAEL A REED

5 Name of your agent (if you know one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY
CN925.1
980 GREAT WEST ROAD
BRENTFORD
MIDDLESEX
TW8 9GS, GB

Patents ADP number (if you know it)

08072555004

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of Filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description

30

Claim(s)

3

Abstract

1

Drawing(s)

-

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 1/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination
(*Patent Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Michael Reed

Signature **MICHAEL A REED** 9 April 2003
AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom

JEAN HARNEY

020 8047 4420

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) **Notes**

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.

e) For details of the fee and ways to pay please contact the Patent Office.

Chemical compounds

The present invention relates to bicyclic derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in therapy.


5 The first corticotropin-releasing factor (CRF) was isolated from ovine hypothalami and identified as a 41-amino acid peptide (Vale et al., Science 213: 1394-1397, 1981). CRF has been found to produce profound alterations in endocrine, nervous and immune system function. CRF is believed to be the major physiological regulator of the basal and 10 stress-release of adrenocortotropic hormone ("ACTH"), Bendorphin and other proopiomelanocortin ("POMC")-derived peptides from the anterior pituitary (Vale et al., Science 213: 1394-1397, 1981).

In addition to its role in stimulating the production of ACTH and POMC, CRF appears to 15 be one of the pivotal central nervous system neurotransmitters and plays a crucial role in integrating the body's overall response to stress.

Administration of CRF directly to the brain elicits behavioral, physiological and endocrine responses identical to those observed for an animal exposed to a stressful environment. Accordingly, clinical data suggests that CRF receptor antagonists may represent novel 20 antidepressant and/or anxiolytic drugs that may be useful in the treatment of the neuropsychiatric disorders manifesting hypersecretion of CRF.


The first CRF receptor antagonists were peptides (see, e.g., Rivier et al., U.S. Patent No. 4,605,642; Rivier et al., Science 224: 889, 1984). While these peptides established that 25 CRF receptor antagonists can attenuate the pharmacological responses to CRF, peptide CRF receptor antagonists suffer from the usual drawbacks of peptide therapeutics including lack of stability and limited oral activity. More recently, small molecule CRF receptor antagonists have been reported.

30 WO 95/10506 describes inter alia compounds of general formula (A) with general CRF antagonist activity



wherein Y may be CR29; V may be nitrogen, Z may be carbon or nitrogen, R3 may correspond to an amine derivative and R4 may be taken together with R29 to form a 5-membered ring and is -CH(R28) when R29 is -CH(R30). There are no specific disclosures 35 of compounds corresponding to this definition.


WO 95/33750 also describes compounds of general formula-(B)-having CRF antagonistic activity,



in which A and Y may be nitrogen and carbon and B may correspond to an amine derivative.


There are no specific disclosures of compounds corresponding to this definition.

WO 98/08846 describes compounds of general formula (C) having CRF antagonistic activity,



wherein A may be carbon, G may be nitrogen or carbon, B may be an amino derivative and the other groups have the meanings as defined.


Recently a patent application has been published as WO 02/08895 in which the following compounds, CRF antagonists, are objects of the Patent Application:



In particular, R₂ and R₃ with N may form a saturated or unsaturated heterocycle, which may be substituted by a 5-6 membered heterocycle, which may be substituted by 1 to 3 groups selected among: C1-C6 alkyl, halo C1-C2 alkyl, C1-C6 alkoxy, halogen, nitro or cyano.

Another recent patent application has been published as WO 03/008412 in which the following compounds, CRF antagonists, are objects of the Patent Application:

25



In particular, R₂ and R₃ with N may form a 5-14 membered heterocycle, which may be substituted by a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more groups such as C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 5 halo C1-C6 alkoxy, hydroxyl, halogen, nitro, cyano, or C(O)NR₆R₇.


Due to the physiological significance of CRF, the development of biologically-active small molecules having significant CRF receptor binding activity and which are capable of antagonizing the CRF receptor remains a desirable goal. Such CRF receptor antagonists 10 would be useful in the treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders in general.

While significant strides have been made toward achieving CRF regulation through administration of CRF receptor antagonists, there remains a need in the art for effective 15 small molecule CRF receptor antagonists. There is also a need for pharmaceutical compositions containing such CRF receptor antagonists, as well as methods relating to the use thereof to treat, for example, stress-related disorders. The present invention fulfills these needs, and provides other related advantages.

20 In particular the invention relates to novel compounds which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors.

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof

25



wherein

30 R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups
G selected from:
halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl,
C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, -NR₃R₄, cyano, and a
group W;

35 R₁ is hydrogen, C1-C6 alkyl, C1-C6 alkoxy; C2-C6 alkenyl, C2-C6 alkynyl,
halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano;

 R₂ is a C1-C4 alkyl, -OR₃ or -NR₃R₄;

 R₃ is hydrogen or C1-C6 alkyl;

	R_4	is hydrogen or C1-C6 alkyl;
	Z	is a 5-6 membered heterocycle, which may be substituted by 1 to 4 R_5 groups;
5	R_5	is a C1-C6 alkyl, halo C1-C2 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, $-NR_3R_4$; $-C(O)R_2$;
	W	is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and in which:
10		- one carbon atom is replaced by a carbonyl or $S(O)_m$; and - one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR_3 , $S(O)_m$, carbonyl, and such ring may be substituted by 1 to four R_6 groups;
	R_6	has the same meanings of R_5 ;
	Y	is nitrogen or $-CR_7$;
15	R_7	hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;
	X	is carbon or nitrogen;
	m	is 0, 1 or 2;
	n	is 1 or 2.

20 The compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt. For a review on suitable salts see Berge et al, J. Pharm. Sci., 1977, 66, 1-19.

25 Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

30 Suitable addition salts are formed from acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, piruvate, oxalate, oxaloacetate, trifluoroacetate, saccharate, benzoate, methansulphonate, ethanesulphonate, benzenesulphonate, p-toluensulphonate, methanesulphonic, ethanesulphonic, p-toluenesulphonic, and isethionate.

35 Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.

40 Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For

example, a complex with water is known as a "hydrate". Solvates of the compound of the invention are within the scope of the invention.

In addition, prodrugs are also included within the context of this invention.

5 As used herein, the term "prodrug" means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and in D. Fleisher, S. Ramon and H. Barbra 10 Association, "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19(2) 115-130, each of which are incorporated herein by reference.

15 Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulphydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, 20 amine or sulphydryl groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol, sulphydryl and amine functional groups of the compounds of structure (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and /or be hydrolysable under *in vivo* 25 conditions in the human body. Suitable pharmaceutically acceptable *in vivo* hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.

30 With regard to stereoisomers, the compounds of structure (I) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.

35 Where a compound of the invention contains an alkenyl or alkenylene group, cis (E) and trans (Z) isomerism may also occur. The present invention includes the individual stereoisomers of the compound of the invention and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.

40 Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the

diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.

Those skilled in the art of organic chemistry will appreciate that many organic compounds
5 can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate". Solvates of the compounds of the invention are within the scope of the invention.

10 Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention.

The term C1-C6 alkyl as used herein as a group or a part of the group refers to a linear or branched alkyl group containing from 1 to 6 carbon atoms; examples of such groups
15 include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert butyl, pentyl or hexyl.

The term C3-C7 cycloalkyl group means a non aromatic monocyclic hydrocarbon ring of 3 to 7 carbon atom such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; while unsaturated cycloalkyls include cyclopentenyl and cyclohexenyl, and
20 the like.

The term halogen refers to a fluorine, chlorine, bromine or iodine atom.

The term halo C1-C6 alkyl, or halo C1-C2 alkyl means an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with halogen such as for example a trifluoromethyl group and the like.
25

The term C2-C6 alkenyl defines straight or branched chain hydrocarbon radicals containing one or more double bond and having from 2 to 6 carbon atoms such as, for
30 example, ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl or 3-hexenyl and the like.

The term C1-C6 alkoxy group may be a linear or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy
35 and the like.

The term halo C1-C6 alkoxy group may be a C1-C6 alkoxy group as defined before substituted with at least one halogen, preferably fluorine, such as OCHF₂, or OCF₃.

40 The term C2-C6 alkynyl defines straight or branched chain hydrocarbon radicals containing one or more triple bond and having from 2 to 6 carbon atoms including acetylenyl, propynyl, 1-butynyl, 1-pentynyl, 3-methyl-1-butynyl and the like.


The term aryl means an aromatic carbocyclic moiety such as phenyl, biphenyl or naphthyl.

The term heteroaryl means an aromatic heterocycle ring of 5 to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 5 1 carbon atom, including both mono-and bicyclic ring systems.

Representative heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindoly!, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, 10 benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, triazolyl, tetrazolyl, and quinazolinyl.

The term 5-6 membered heterocycle means, according to the above definition, a 5-6 monocyclic heterocyclic ring which is either saturated, unsaturated or aromatic, and which 15 contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Heterocycles include heteroaryls as defined above. The heterocycle may be attached via any heteroatom or carbon atom. Thus, the term include (but are not limited to) morpholinyl, pyridinyl, pyrazinyl, pyrazolyl, 20 thiazolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofurananyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

25 Representative ring of the W definition include the following structure and derivatives, but are not limited to:



30 in which:

W1 represents a 1,3-dihydro-2H-imidazol-2-one derivative;

W2 represents a imidazolidin-2-one derivative;


W3 represents a tetrahydropyrimidin-2(1H)-one derivative;

W4 represents a 2,5-dihydro-1,2,5-thiadiazole 1-oxide derivative;

W5 represents a 1,2,5-thiadiazolidine 1-oxide derivative;
 W6 represents a 2,5-dihydro-1,2,5-thiadiazole 1,1-dioxide derivative;
 W7 represents a 1,2,6-thiadiazinane 1-oxide derivative;
 W8 represents a 1,2,6-thiadiazinane 1,1-dioxide derivative;
 5 W9 represents a pyrrolidin-2-one derivative;
 W10 represents a 2,5-dihydro-1,2,5-thiadiazolidine 1,1-dioxide derivative;
 and R₆ which may be multiple, is defined as above.


Representative compounds of this invention include the following structure (Ia) and (Ib)

10




In one preferred embodiment in which n is 1, according to the definition of the compounds of formula (I) above, the CRF receptor antagonists of this invention have structure (Ia),
 15 and, when n is 2, then the CRF receptor antagonists of this invention have structure (Ib), wherein R, R₁, R₂ and R₃ are defined as above.


Depending upon the choice of X, the CRF receptor antagonists of this invention include compounds of formula (II) in which X corresponds to nitrogen atom and R, R₁, R₄, Z, Y
 20 and W have the meanings defined above.



Depending upon the choice of Y, the CRF receptor antagonists of this invention include compounds of formula (III) and (IV), in which Y is carbon or nitrogen, and R, R₁, R₇, Z and W have the meanings defined above.
 25




Preferred compounds of the present invention are the compounds of formula (IIIa), corresponding to the compounds of formula (III), in which Z corresponds to a pyrazole derivative, R₇ is hydrogen and R, R₁, R₅, and W have the meanings defined above.




5

Particularly preferred are the compounds of formula (Va), (Vb) and (Vc), corresponding to the compounds of formula (IIIa), in which R₇ and R₅ are both hydrogen and W corresponds to the groups W2, W3 and W9.


10



(Va)



(Vb)



(Vc)

Examples of such compounds are reported in the Experimental Part.

15 Even more preferred embodiments of the invention include, but are not limited to, compounds of the formula (I), (Ia), (Ib), (II), (III), (IIIa), (IV), (Va), (Vb), (Vc) wherein:

- 20 R₁ is C1-C3 alkyl group or halo C1-C3 alkyl group, preferably methyl or trifluoromethyl; R₄ is hydrogen; and
- 25 R is an aryl group selected from: 2,4-dichlorophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-trifluoromethyl, 2-chloro-4-methoxyphenyl, 2,4,5-trimethylphenyl, 2,4-dimethylphenyl, 2-methyl-4-methoxyphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-trifluoromethyl, 2,4-dimethoxyphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-chlorophenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-methylphenyl, 2-trifluoromethyl-4-chlorophenyl, 2,4-trifluoromethylphenyl, 2-trifluoromethyl-4-methylphenyl, 2-trifluoromethyl-4-methoxyphenyl, 2-bromo-4-isopropylphenyl, 2-methyl-4-cyanophenyl, 2-chloro-4-cyanophenyl, 2-methyl-4-trifluoromethoxyphenyl, 4-methyl-6-dimethylaminopyridin-3-yl, 2,6-bismethoxy-pyridin-3-yl,

2-methyl-6-methoxy-pyridin-3-yl, 2-trifluoromethyl-6-methoxy-pyridin-3-yl and 3-chloro-5-trichloromethyl-pyridin-2-yl.


Preferred compounds according to the invention are:

5 1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}imidazolidin-2-one (compound 1-1);
 1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}-3-methylimidazolidin-2-one (compound 1-2);
 1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}pyrrolidin-2-one (compound 2-1);
 1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}tetrahydropyrimidin-2(1*H*)-one (compound 3-1).

In general, the compounds of structure (I) may be made according to the organic synthesis techniques known to those skilled in this field, as well as by the representative methods set forth in the Examples.

Compounds of formula (I), and salts and solvates thereof, may be prepared by the general methods outlined hereinafter. In the following description, the groups R, R₁, R₂,
 20 R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, and n have the meanings as previously defined for compounds of formula (I) unless otherwise stated.

Compounds of formula (IIIa) may be conveniently prepared, starting from compounds of formula (V), in which R, R₁ R₅ and W are defined as above, according to the following
 25 Scheme 1:



in which:

step a stands for the formation of the pyrrolidinone moiety of compounds (VI), which will form the cycle B present in the final compounds (IIIa), by reacting the compounds (V) with a reactive derivative of the butyric acid, such as 4-chlorobutyryl chloride; followed by a cyclisation reaction in basic conditions (e.g. KOtBu);
 30

step b stands for amidine formation by reacting the compounds (VI) with 3-aminocrotonate and POCl_3 ;

step c stands for the cyclisation of the compounds (VII) in basic conditions (e.g. NaH) to give the pyridinone precursor of cycle A in the final compounds (IIIa);

5 step d stands for the formation of a reactive derivative (i.e. a leaving group, Lg) of the pyridinone (for example selected in a group consisting by triflate, halogen, mesylate) of compounds (VIII) by reaction with, for example, triflic anhydride;


10 step e stands for nucleophilic displacement of the leaving group of compounds (IX) to give the iodinated compounds (X);

step f stands for the arylation reaction with the suitable pyrazole derivative by a metal catalysed coupling reaction (for example a Buchwald reaction) procedure to give the final compounds (IIIa).

15 The starting compounds of formula (V) are known compounds or may be prepared according to known methods in the literature.

20 The pyrazole moieties of compounds (IIIa) are new compounds and may be prepared according to the following Schemes.

Scheme for the synthesis of 1-(1*H*-pyrazol-3-yl)imidazolidin-2-one




25 in which

step a' stands for the reaction of 3-aminopyrazole with chloroethyl isocyanate in DMF at 0°C ;

step b' stands for cyclisation reaction with KOt-Bu in THF at r.t.;

step c' stands for deprotection reaction by LiOH in $\text{MeOH}/\text{H}_2\text{O}$ at 80°C .

30 Scheme for the synthesis of 1-(1*H*-pyrazol-3-yl)pyrrolidin-2-one



intermediate 10

in which


step a" stands for reaction of 3-aminopyrazole with 4-chloro butyryl chloride in presence of K_2HPO_4 , and in CH_2Cl_2 ;

step b" stands for cyclisation reaction with NaH , in DMF, at r.t.;

step c" stands for deprotection reaction by $MeONa/MeOH$, at r.t..

5

Scheme for the synthesis of 1-(1*H*-pyrazol-3-yl)tetrahydropyrimidin-2(1*H*)-one



intermediate 13

in which

step a" stands for the reaction of 3-aminopyrazole with chloropropyl isocyanate, in DMF, at 0°C;

step b" stands for cyclisation reaction with $KOt\text{-}Bu$, in THF, at r.t.;

step c" stands deprotection reaction by $LiOH$, in $MeOH/H_2O$, at 80°C.

10

Those skilled in the art will appreciate that in the preparation of the compound of the invention or a solvate thereof it may be necessary and/or desirable to protect one or more sensitive groups in the molecule to prevent undesirable side reactions. Suitable protecting groups for use according to the present invention are well known to those skilled in the art and may be used in a conventional manner. See, for example, "Protective groups in organic synthesis" by T.W. Greene and P.G.M. Wuts (John Wiley & sons 1991) or

"Protecting Groups" by P.J. Kocienski (Georg Thieme Verlag 1994). Examples of suitable amino protecting groups include acyl type protecting groups (e.g. formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g. benzyloxycarbonyl (Cbz) and substituted Cbz), aliphatic urethane protecting groups (e.g. 9-fluorenylmethoxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), isopropylloxycarbonyl, cyclohexyloxycarbonyl) and alkyl type protecting groups (e.g. benzyl, trityl, chlorotriptyl). Examples of suitable oxygen protecting groups may include for example alky silyl groups, such as trimethylsilyl or tert-butyldimethylsilyl; alkyl ethers such as tetrahydropyranyl or tert-butyl; or esters such as acetate

Pharmaceutical acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compound of formula (I) using conventional methods.

The compounds of formula (I) may readily be isolated in association with solvent molecules by crystallisation or evaporation of an appropriate solvent to give the corresponding solvates.

When a specific enantiomer of a compound of general formula (I) is required, this may be obtained for example by resolution of a corresponding enantiomeric mixture of a

compound of formula (I) using conventional methods. Thus the required enantiomer may be obtained from the racemic compound of formula (I) by use of chiral HPLC procedure.

The subject invention also includes isotopically-labelled compounds, which are identical
5 to those recited in formula (I) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, 10 fluorine, iodine, and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I and ^{125}I .

Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as ^3H , ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. ^{11}C and ^{18}F isotopes are particularly useful in PET (positron emission tomography), and ^{125}I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of formula I and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

30 The CRF receptor antagonists of the present invention demonstrate activity at the CRF receptor site including CRF 1 and CRF 2 receptors and may be used in the treatment of conditions mediated by CRF or CRF receptors.

35 The effectiveness of a compound as a CRF receptor antagonist may be determined by various assay methods. Suitable CRF antagonists of this invention are capable of inhibiting the specific binding of CRF to its receptor and antagonizing activities associated with CRF. A compound of structure (I) may be assessed for activity as a CRF antagonist by one or more generally accepted assays for this purpose, including (but not limited to) the assays disclosed by DeSouza et al. (J. Neuroscience 7: 88,1987) and Battaglia et al. 40 (Synapse 1: 572,1987).

The CRF receptors-binding assay was performed by using the homogeneous technique of scintillation proximity (SPA). The ligand binds to recombinant membrane preparation

expressing the CRF receptors which in-turn bind to wheatgerm agglutinin coated SPA beads. In the Experimental Part will be disclosed the details of the experiments.

With reference to CRF receptor binding affinities, CRF receptor antagonists of this
5 invention have a Ki less than 10 μ m.

Compounds of the invention are useful in the treatment of central nervous system disorders where CRF receptors are involved. In particular in the treatment or prevention of major depressive disorders including bipolar depression, unipolar depression, single or
10 recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, the treatment of anxiety and the treatment of panic disorders. Other mood disorders encompassed within the term major depressive disorders include dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders,
15 post operative stress and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood. Major
20 depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.

Compounds of the invention are also useful in the treatment or prevention of schizophrenic disorders including paranoid schizophrenia, disorganized schizophrenia,
25 catatonic schizophrenia, undifferentiated schizophrenia, residual schizophrenia.

Compounds of the invention are useful as analgesics. In particular they are useful in the treatment of traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid
30 or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain; various forms of headache such as migraine,
35 acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmenorrhoea; menstrual pain; meningitis; arachnoiditis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing spondylitis; gout; burns; scar pain; itch; and thalamic pain
40 such as post stroke thalamic pain.

Compounds of the invention are also useful for the treatment of dysfunction of appetite and food intake and in circumstances such as anorexia, anorexia nervosa and bulimia.

Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadian rhythmic disorders.

5 Compounds of the invention are also useful in the treatment or prevention of cognitive disorders. Cognitive disorders include dementia, amnestic disorders and cognitive disorders not otherwise specified.

Furthermore compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.

10 Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds),
15 or in the treatment of tolerance to and dependence on opiates (e.g. cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative hypnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.

20 Compounds of the invention are also useful as anti-inflammatory agents. In particular they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD) and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such
25 as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.

30 Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.

35 Compounds of the invention are also useful in the treatment of emesis, i.e. nausea, retching and vomiting. Emesis includes acute emesis, delayed emesis and anticipatory emesis. The compounds of the invention are useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as
40 cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection;

pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; decreased intracranial pressure (e.g. altitude sickness);

5 opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.

10 Compounds of the invention are of particular use in the treatment of gastrointestinal disorders such as irritable bowel syndrome (IBS); skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischaemia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases such as scleroderma and eosinophilic fasciitis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and rheumatic diseases such as fibrositis; and cough.

15

20 Compounds of the invention are useful for the treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral vasospasm, hypoglycemia, hypoxia, anoxia, perinatal asphyxia cardiac arrest.

The invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.

25 There is also provided as a further aspect of the invention the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by CRF.

30 In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular in the treatment of condition mediated by CRF, comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or a solvate thereof.

35 While it is possible that, for use in therapy, a compound of the present invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation e. g. when the agent is in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

40 In a further aspect, the invention provides a pharmaceutical composition comprising at least one compound of the invention or a pharmaceutically acceptable derivative thereof in association with a pharmaceutically acceptable carrier and/or excipient. The carrier and/or excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Accordingly, the present invention further provides a pharmaceutical formulation comprising at least one compound of the invention or a pharmaceutically acceptable derivative thereof, in association with a pharmaceutically acceptable carrier and/or excipient. The carrier and/or excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

There is further provided by the present invention a process of preparing a pharmaceutical composition, which process comprises mixing at least one compound of the invention or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable carrier and/or excipient.

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier or excipient. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as – or in addition to – the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit though the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets

containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration,

5 compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

10 For some embodiments, the agents of the present invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drugcyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e. g. as a carrier, diluent or solubiliser. Alpha-, beta and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

15 20 In a preferred embodiment, the agents of the present invention are delivered systemically (such as orally, buccally, sublingually), more preferably orally.

Hence, preferably the agent is in a form that is suitable for oral delivery.

25 It is to be understood that not all of the compounds need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.

30 The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention may be prepared by processes known in the art, for example see International Patent Application No. WO 02/00196 (SmithKline Beecham).

35 40 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for

constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the composition may take the form of tablets or formulated in conventional manner.

The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.

Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.

The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for

example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

For intranasal administration, the compounds of the invention may be formulated as
 5 solutions for administration via a suitable metered or unitary dose device or alternatively
 as a powder mix with a suitable carrier for administration using a suitable delivery device.

A proposed dose of the compounds of the invention is 1 to about 1000mg per day. It will
 be appreciated that it may be necessary to make routine variations to the dosage,
 10 depending on the age and condition of the patient and the precise dosage will be
 ultimately at the discretion of the attendant physician or veterinarian. The dosage will also
 depend on the route of administration and the particular compound selected.
 Thus for parenteral administration a daily dose will typically be in the range of 1 to about
 15 100 mg, preferably 1 to 80 mg per day. For oral administration a daily dose will typically
 be within the range 1 to 300 mg e.g. 1 to 100 mg.

EXAMPLES

In the Intermediates and Examples unless otherwise stated:

20 Melting points (m.p.) were determined on a Gallenkamp m.p. apparatus and are uncorrected. All temperatures refers to °C. Infrared spectra were measured on a FT-IR instrument. Proton Magnetic Resonance (¹H-NMR) spectra were recorded at 400 MHz, chemical shifts are reported in ppm downfield (d) from Me₄Si, used as internal standard,
 25 and are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Column chromatography was carried out over silica gel (Merck AG Darmstaadt, Germany). The following abbreviations are used in text: EtOAc = ethyl acetate, cHex = cyclohexane, CH₂Cl₂ = dichloromethane, Et₂O = dietyl ether, DMF = N,N'-dimethylformamide, DIPEA=N,N-diisopropylethylamine, DME = ethylene glycol
 30 dimethyl ether, MeOH = methanol, Et₃N = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran; DIBAL-H=diisobutylaluminium hydride, DMAP=dimethylaminopyridine, LiHMDS= lithiumhexamethyldisilazane, KOtBu= potassium tert-butoxide, NMP= M-methyl-2-pyrrolidinone; SCX= strong cation exchanger; TLC refers to thin layer chromatography on silica plates, and dried refers to a solution dried over anhydrous sodium sulphate; r.t. (RT)
 35 refers to room temperature.

Intermediate 1

1-(4-Methoxy-2-methylphenyl)pyrrolidin-2-one

40 To a solution of Et₃N (156 mL, 1 eq) and 4-methoxy-2-methylaniline (150 g, 1.09 mole) in anh. THF (2.4 L), in a 10 L reaction vessel, at 0°C, under N₂, was added dropwise a solution of 4-chlorobutyryl chloride (126 mL, 1 eq) in anh. THF (480 mL). The internal

temperature was maintained at *circa* 10°C and the reaction mixture was stirred for 1.5 hr. It was cooled down to 0°C and KO*t*-Bu 1M/THF (2.64 L, 2.4 eq) was added dropwise over a period of 1.5 hr, keeping the internal temperature <10°C. The reaction mixure was stirred at that temperature for 30 min. Water (1.5 L) was then added slowly (20 min) and the phases were separated. The organic layer was treated with conc. HCl (250 mL) and water (1.26 L) and the phases were separated. The combined aqueous layers were extracted with EtOAc (2.6 L) and the combined organic layers were washed with brine (2 L). The solvent was evaporated and the residue purified by flash chromatography (Biotage 150, EtOAc/cHex 8:2) to give the title compound as a pale brown solid (206 g, 92%).
¹H NMR (¹H, CDCl₃): δ 7.05 (d, 1H), 6.79-6.72 (m, 2H), 3.75 (s, 3H), 3.64 (t, 2H), 2.18 (s, 6H).
MS (m/z): 206 [MH]⁺.

15 Intermediate 2
Ethyl 3-[(1-(4-methoxy-2-methylphenyl)pyrrolidin-2-ylidene]amino}but-2-enoate

To a solution of intermediate 1 (8.3 g, 40.49 mmols) in anh. 1,2-dichloroethane (100 mL), at r.t., under N₂, was added POCl₃ (7.5 mL, 2 eq) dropwise followed by ethyl 3-aminocrotonate (5.17 mL, 1 eq). The reaction mixture was heated at 60°C for 3.5 hr. It was then cooled down to r.t. and neutralized to pH 7 by the carefull addition of sat.aq. NaHCO₃. The neutralized solution was extracted with CH₂Cl₂ (3 x 50 mL). The combined organic extracts were washed with sat.aq. NaCl and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was used as such in the next step (17.8 g).
MS (m/z): 317 [MH]⁺.

30 Intermediate 3
1-(4-Methoxy-2-methylphenyl)-6-methyl-1,2,3,7-tetrahydro-4*H*-pyrrolo[2,3-*b*]pyridin-4-one

A solution of intermediate 2 (17.8 g, 55 mmols) in anh. DMF (50 mL) was added dropwise to a suspension of NaH 60%/oil (4.5 g, 2 eq) in anh. DMF. The reaction mixture was heated at 100°C for 8 hr. More NaH 60%/oil (2.25 g, 1 eq) was added and the reaction mixture was heated for an additional 4 hr. It was cooled down to r.t. and carefully poured in sat.aq. NH₄Cl. The aqueous solution was extracted with CH₂Cl₂ (5 x 50 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent was evaporated. The crude compound was purified by flash chromatography (Biotage 75, CH₂Cl₂/MeOH 95:5 → 80:20). The title compound was obtained as a brown oil (952 mg, 9%, two steps)

NMR (^1H , CDCl_3): δ 7.08 (d, 1H), 6.72-6.68 (m, 2H), 5.87 (s, 1H), 3.73 (s, 3H), 3.73 (t, 2H), 2.99 (t, v2H), 2.21 (s, 3H), 2.13 (s, 3H).
 MS (m/z): 271 [MH]⁺.

5 Intermediate 4

1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl trifluoromethanesulfonate

10 To a solution of intermediate 3 (950 mg, 3.52 mmols) in anh. CH_2Cl_2 (10 mL), at -20°C, under N_2 , were added pyridine (626 μL , 2.2 eq) and triflic anhydride (651 μL , 1.1 eq). The reaction mixture was stirred at r.t. for 2 hr. It was then poured in sat.aq. NH_4Cl (20 mL) and the phases were separated. The aqueous layer was extracted with CH_2Cl_2 (2 x 10 mL) and the combined organic extracts were dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a white solid (913 mg, 64%).

15

Intermediate 5

20 NMR (^1H , CDCl_3): δ 7.12 (d, 1H), 6.81-6.75 (m, 2H), 6.24 (s, 1H), 3.89 (t, 2H), 3.80 (s, 3H), 3.21 (t, 2H), 2.29 (s, 3H), 2.21 (s, 3H).
 MS (m/z): 403 [MH]⁺.

Intermediate 5

25 4-Iodo-1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridine

To a solution of intermediate 4 (913 mg, 2.27 mmols) in anh. NMP (7 mL) was added KI (1.13 g, 3 eq) and the reaction mixture was stirred at 150°C for 18 hr. It was then cooled down to r.t. and diluted in water/sat.aq. NaCl. The aqueous phase was extracted with EtOAc (3 x 30 mL) and the combined organic extracts were dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a clear oil, which solidified upon standing (681 mg, 79%).

30

35 NMR (^1H , CDCl_3): δ 7.14 (d, 1H), 6.81-6.74 (m, 2H), 6.70 (s, 1H), 3.84 (t, 2H), 3.81 (s, 3H), 3.03 (t, 2H), 2.22 (s, 6H).
 MS (m/z): 381 [MH]⁺.

Intermediate 6

40 *N*-(2-Chloroethyl)-3-({[(2-chloroethyl)amino]carbonyl}amino)-1*H*-pyrazole-1-carboxamide

To a solution of 3-aminopyrazole (500 mg, 6 mmol) in anh. DMF (3 mL), at 0°C, under N₂, was added 3-chloroethyl isocyanate (1.53 mL, 3 eq) and the reaction mixture was stirred at r.t. for 2 hr, after which the solvent was evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound (1.593 g, 89%).

NMR (¹H, DMSO): δ 9.20 (s, 1H), 8.26 (m, 1H), 8.10 (d, 1H), 7.25 (bs, 1H), 6.37 (d, 1H), 3.74 (m, 2H), 3.66 (m, 2H), 3.58 (m, 2H), 3.46 (m, 2H).

MS (m/z): 296 [MH]⁺.

10 Intermediate 7
N-(2-Chloroethyl)-3-(2-oxoimidazolidin-1-yl)-1*H*-pyrazole-1-carboxamide

To a solution of intermediate 6 (100 mg, 0.34 mmol) in anh. THF (4 mL), at r.t., under N₂, was added KOt-Bu (42 mg, 1.1 eq) and the reaction mixture was stirred for 2 hr. Water (0.5 mL) was added and the solvent was evaporated. The aqueous phase was diluted with H₂O and extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 8:2, then 9:1) to give the title compound as a white solid (39 mg, 44%).

NMR (¹H, DMSO): δ 8.18 (bt, 1H), 8.11 (d, 1H), 7.14 (bs, 1H), 6.75 (d, 1H), 3.89 (m, 2H), 3.73 (m, 2H), 3.56 (m, 2H), 3.40 (m, 2H).

MS (m/z): 258 [MH]⁺.

25 Intermediate 8
1-(1*H*-Pyrazol-3-yl)imidazolidin-2-one

To a solution of intermediate 7 (190 mg, 0.74 mmol) in a 2:1 mixture of MeOH/H₂O (15 mL), at r.t., under N₂ was added LiOH (177 mg, 10 eq) and the reaction mixture was heated at 80°C for 3 hr. It was cooled down to r.t. and neutralized to pH 7 with 2M HCl. Silica gel was then added and the solvents were evaporated. The adsorbed crude product was purified by flash chromatography (silica gel, EtOAc/MeOH 9:1) to give the title compound as a white solid (80 mg, 71%).

NMR (¹H, DMSO): δ 12.10 (bs, 1H), 7.6 (s, 1H), 6.7 (s, 1H), 6.4 (s, 1H), 3.8 (t, 2H), 3.4 (t, 2H).

MS (m/z): 152 [MH]⁺.

40 Intermediate 9
4-Chloro-N-[1-(4-chlorobutanoyl)-1*H*-pyrazol-3-yl]butanamide

To a solution of 3-aminopyrazole (300 mg, 3.61 mmol) in anh. CH_2Cl_2 (6 mL), at r.t., under N_2 , was added K_2HPO_4 (1.26 g, 2 eq) and the reaction mixture was stirred at r.t. for 15 min. 4-Chloro-butyryl chloride (406 μL , 3.6 mmols) was then added and the reaction mixture was stirred for 24 hr. It was then poured into water and the phases were separated. The aqueous layer was extracted with EtOAc (2 x 20 mL) and the combined organic extracts were dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a white solid (354 mg, 34%).
 NMR (^1H , CDCl_3): δ 8.09 (d, 1H), 7.83 (bs, 1H), 6.98 (s, 1H), 3.64 (m, 2H), 3.17 (m, 1H), 2.57 (m, 1H), 2.21 (m, 2H).
 MS (m/z): 292 [M]⁺.

Intermediate 101-(1*H*-Pyrazol-3-yl)pyrrolidin-2-one

To a suspension of NaH 80%/oil (31 mg, 1.1 eq) in anh. DMF (1.5 mL), at r.t., under N_2 , was added a solution of intermediate 9 (340 mg, 1.16 mmol) in anh. DMF (1 mL). The reaction mixture was stirred at r.t. for 1 hr, after which it was quenched carefully with water. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic extracts were washed with sat.aq. NaCl and dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product (70 mg, 0.27 mmol) was dissolved in anh. MeOH (3 mL), at r.t., under N_2 , and 1M MeONa/MeOH was added until pH 9 was reached. The reaction mixture was stirred at r.t. for 30 min and water was added. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic extracts were washed with sat.aq. NaCl and dried over Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (cHex/EtOAc 7:3) to give the title compound as a white solid (35 mg, 20%).
 NMR (^1H , CDCl_3): δ 7.46 (s, 1H), 6.55 (s, 1H), 3.90 (t, 2H), 2.59 (t, 2H), 2.18 (m, 2H).
 MS (m/z): 152 [M]⁺.

Intermediate 11*N*-(3-chloropropyl)-3-({[(3-chloropropyl)amino]carbonyl}amino)-1*H*-pyrazole-1-carboxamide

To a solution of 3-aminopyrazole (500 mg, 6 mmol), in anh. DMF (10 mL), at r.t., under N_2 , was added 3-chloropropyl isocyanate (1.2 mL, 2 eq) and the reaction was stirred for 24 hr. The reaction was not complete and more isocyanate (1.2 mL, 2 eq) was added. The reaction mixture was stirred for an additional 48 hr. It was then poured into CH_2Cl_2 /sat.aq. NaCl and the phases were separated. The aqueous layer was extracted with CH_2Cl_2 (2 x 20 mL) and the combined organic extracts were dried over anh. Na_2SO_4 .

The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (Biotage 40, cHex/EtOAc 7:3) to give the title compound as a white solid (620 mg, 32%).

5 NMR (^1H , DMSO): δ 9.05 (s, 1H), 8.25 (t, 1H), 8.08 (d, 1H), 7.17 (t, 1H), 6.30 (d, 1H), 4.7-4.6 (m, 4H), 3.37 (q, 2H), 3.26 (q, 2H), 2.05-1.87 (m, 4H).

MS (m/z): 322 [MH] $^+$.

Intermediate 12

N-(3-Chloropropyl)-3-(2-oxotetrahydropyrimidin-1(2H)-yl)-1*H*-pyrazole-1-carboxamide

10 To a solution of intermediate 11 (620 mg, 1.93 mmol) in anh. THF (20 mL), at r.t., under N_2 , was added KO*t*-Bu (237 mg, 1.1 eq). The reaction mixture was stirred at r.t. for 2 hr. Water was then added and the solvent was evaporated. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (Flash Master, 10g SiO₂, cHex/EtOAc 7:3, then 100% EtOAc) to give the title compound as a white solid (200 mg, 37%).

15 NMR (^1H , DMSO): δ 8.23 (t, 1H), 8.06 (d, 1H), 6.93 (bs, 1H), 6.82 (d, 1H), 3.86 (t, 2H), 3.57 (t, 2H), 3.34 (m, 2H), 3.19 (m, 2H), 1.98 (m, 2H), 1.91 (m, 2H).

20 MS (m/z): 286 [MH] $^+$.

Intermediate 13

1-(1*H*-Pyrazol-3-yl)tetrahydropyrimidin-2(1*H*)-one


25 A solution of intermediate 12 (180 mg; 0.63 mmol) and LiOH (265 mg, 10 eq) in a 2:1 mixture of MeOH/H₂O (7.5 mL), in a sealed vial, was treated with microwave irradiation (80°C) for 10 min. The reaction mixture was then cooled down to r.t., and the solvent was evaporated to dryness. The residue was purified on an SCX cartridge (EtOAc/MeOH 8:2, then 100% MeOH) to give the title compound as a white solid (102 mg, 98%).

30 NMR (^1H , DMSO): δ 12.13 (bs, 1H), 7.50 (s, 1H), 6.60 (bs, 1H), 6.46 (s, 1H), 3.73 (m, 2H), 3.15 (m, 2H), 1.88 (m, 2H).

35 MS (m/z): 167 [MH] $^+$.

EXAMPLE 1

Synthesis of representative compounds of structure

**Example 1-1****1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one**


5 In a sealed vial, at r.t., under N_2 , are mixed together intermediate 5 (60 mg, 0.158 mmol), CuI (6 mg, 0.2 eq) and K_2CO_3 (4.5 mg, 2.5 eq). A solution of dodecane (14.3 μ L, 0.4 eq), *trans*-cyclohexanediamine (14 μ L, 0.6 eq) and intermediate 8 (48 mg, 2 eq) in anh. NMP (5 mL) was added and the reaction mixture was stirred at 130°C for 3.5 hr. It was then
10 cooled down to r.t. and poured in EtOAc/H₂O. The phases were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (EtOAc/cHex 6:4, then 1:1, then 3:7)
15 followed by an SCX cartridge (100% MeOH, then 2M NH₃/MeOH) to give the title compound as a white solid (34 mg, 53%)

Example 1-2**1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-3-methylimidazolidin-2-one**

20 To a solution of example 1 (20 mg, 0.05 mmol) in anh. THF (1 mL), at r.t., under N_2 , was added $KOt-Bu$ (5 mg, 1 eq) and the reaction mixture was stirred for 15 min. Methyl iodide (6 μ L, 2 eq) was then added and the reaction mixture was stirred at r.t. for 3 hr. It was then poured into EtOAc/H₂O and the phases were separated. The aqueous layer was extracted with EtOAc (2 x 20 mL) and the combined organic extracts were dried over anh.
25 Na_2SO_4 . The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound as a yellow solid (6 mg, 29%).


All the analytical data are set forth in the following Table 1-1.

30



Cpd. No.	R	R ₁	R ₃	Analytical Data
1-1	2-methyl-4-methoxy-phenyl	CH ₃	H	NMR (¹ H, CDCl ₃): δ 8.29 (d, 1H), 7.15 (d, 1H), 7.04 (s, 1H), 6.85 (d, 1H), 6.79-6.74 (m, 3H), 3.91 (t, 2H), 3.82 (t, 2H), 3.75 (s, 3H), 3.44 (t, 4H), 2.17 (s, 3H), 2.15 (s, 3H) MS (m/z): 405 [MH] ⁺
1-2	2-methyl-4-methoxy-phenyl	CH ₃	CH ₃	NMR (¹ H, CDCl ₃): δ 7.76 (d, 1H), 7.15 (d, 1H), 6.93 (d, 1H), 6.77 (d, 1H), 6.75 (dd, 1H), 6.52 (s, 1H), 3.96 (t, 2H), 3.84 (t, 2H), 3.77 (s, 3H), 3.50 (t, 2H), 3.42 (t, 2H), 3.89 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H) MS (m/z): 419 [MH] ⁺ .

EXAMPLE 2
Synthesis of representative compounds of structure



5

Example 2-1**1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]pyrrolidin-2-one**

In a sealed vial, at r.t., under N₂, are mixed together intermediate 5 (50 mg, 0.16 mmol),
 10 CuI (6 mg, 0.2 eq) and K₂CO₃ (46 mg, 2.1 eq). A solution of dodecane (14.5 μL, 0.4 eq),
trans-cyclohexanediamine (11.5 μL, 0.6 eq) and intermediate 10 (30 mg, 1.2 eq) in anh.
 NMP (1.5 mL) was added and the reaction mixture was treated with microwave
 irradiation (150°C) for three cycles (5 min, 10 min, 15 min). It was then cooled down to
 r.t. and poured in EtOAc/H₂O. The phases were separated and the aqueous layer was
 extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over anh.
 Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was
 purified on a first SCX cartridge (cHex/EtOAc 9:1), a second SCX cartridge
 (CH₂Cl₂/MeOH 9:1) and finally preparative HPLC to give the title compound as a pale
 yellow solid (21 mg, 35%)


20

All the analytical data are set forth in the following Table 2-1.

Cpd. No.	R	R ₁	Analytical Data
2-1	2-methyl-4-methoxy-phenyl	CH ₃	NMR (¹ H, DMSO): δ 8.35 (d, 1H), 7.20 (d, 1H), 6.95 (d, 1H), 6.85 (d, 1H), 6.75 (m, 2H), 3.90 (m, 4H), 3.70 (s, 3H), 3.45 (t, 2H), 2.50 (m, 2H), 2.15 (s, 3H), 2.10 (m, 2H), 2.10 (s, 3H). MS (m/z): 404 [MH] ⁺

EXAMPLE 3

Synthesis of representative compounds of structure (IIIa)



5

Example 3-11-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydropyrimidin-2(1H)-one

In a sealed vial, at r.t., under N₂, are mixed together intermediate 5 (15 mg, 0.04 mmol), 10 CuI (1.5 mg, 0.2 eq) and K₂CO₃ (11.6 mg, 2.1 eq). A solution of dodecane (2 μL, 0.2 eq), *trans*-cyclohexanediamine (2 μL, 0.3 eq) and intermediate 13 (8 mg, 1 eq) in anh. NMP (2 mL) was added and the reaction mixture was stirred at 130°C for 6 hr. It was then cooled down to r.t. and poured in EtOAc/H₂O. The phases were separated and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on an SCX cartridge (EtOAc/cHex 6:4, then 100% EtOAc, then, 5% MeOH/EtOAc) to give the title compound as a white solid (5.1 mg, 25%)

All the analytical data are set forth in the following Table 3-1.

20

Cpd. No.	R	R ₁	Analytical Data
3-1	2-methyl-4-methoxy-phenyl	CH ₃	NMR (¹ H, CDCl ₃): δ 7.80 (d, 1H), 7.2 (d, 1H), 7.0 (d, 1H), 6.80 (d, 1H), 6.75 (dd, 1H), 6.60 (s, 1H), 4.95 (bs, 1H), 4.05 (dd, 2H), 3.90 (t, 2H), 3.80 (s, 3H), 3.45 (t, 2H), 3.40 (bm, 2H), 2.45 (s, 3H), 2.25 (s, 3H), 2.05 (m, 2H). MS (m/z): 419 [MH] ⁺

EXAMPLE 4
CRF Binding Activity

5 CRF binding affinity has been determined in vitro by the compounds' ability to displace ^{125}I -oCRF and ^{125}I -Sauvagine for CRF1 and CRF2 SPA, respectively, from recombinant human CRF receptors expressed in Chinese Hamster Ovary (CHO) cell membranes. For membrane preparation, CHO cells from confluent T-flasks were collected in SPA buffer, (HEPES/KOH 50mM, EDTA 2mM; MgCl_2 10mM, pH 7.4.) in 50mL centrifuge tubes, 10 homogenized with a Polytron and centrifuged (50'000g for 5min at 4°C; Beckman centrifuge with JA20 rotor). The pellet was resuspended, homogenized and centrifuged as before.

15 The SPA experiment has been carried out in Optiplate by the addition of 100 μL the reagent mixture to 1 μL of compound dilution (100% DMSO solution) per well. The assay mixture was prepared by mixing SPA buffer, WGA SPA beads (2.5 mg/mL), BSA (1 mg/mL) and membranes (50 and 5 μg of protein/mL for CRF1 and CRF2 respectively) and 50 pM of radioligand.

20 The plate was incubated overnight (>18 hrs) at room temperature and read with the Packard Topcount with a WGA-SPA ^{125}I counting protocol.

EXAMPLE 5
CRF functional assay

25 Compounds of the invention were characterised in a functional assay for the determination of their inhibitory effect. Human CRF-CHO cells were stimulated with CRF and the receptor activation was evaluated by measuring the accumulation of cAMP. CHO cells from a confluent T-flask were resuspended with culture medium without G418 and dispensed in a 96-well plate, 25'000c/well, 100 μL /well and incubated overnight. After 30 the incubation the medium was replaced with 100 μL of cAMP IBMX buffer warmed at 37°C (5mM KCl, 5mM NaHCO_3 , 154mM NaCl, 5mM HEPES, 2.3mM CaCl_2 , 1mM MgCl_2 ; 1g/L glucose, pH 7.4 additioned by 1mg/mL BSA and 1mM IBMX) and 1 μL of antagonist dilution in neat DMSO. After 10 additional minutes of incubation at 37°C in a plate incubator without CO₂, 1 μL of agonist dilution in neat DMSO was added. As before, the 35 plate was incubated for 10 minutes and then cAMP cellular content was measured by using the Amersham RPA 538 kit.

40 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.


It is to be understood that the present invention covers all combinations of particular and preferred groups described herein above.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:

5.

Claims

1. Compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof



5

wherein

R

is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups
G selected from:

10

halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl,
C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, -NR₃R₄, cyano, and a
group W;

R₁

is hydrogen, C1-C6 alkyl, C1-C6 alkoxy; C2-C6 alkenyl, C2-C6 alkynyl,
halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano;

15

R₂

is a C1-C4 alkyl, -OR₃ or -NR₃R₄;

R₃

is hydrogen or C1-C6 alkyl;

R₄

is hydrogen or C1-C6 alkyl;

Z

is a 5-6 membered heterocycle, which may be substituted by 1 to 4 R₅
groups;

20

R₆

is a C1-C6 alkyl, halo C1-C2 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy,
C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;

W

is a 4-8 membered ring, which may be saturated or may contain one to
three double bonds, and

in which:

25

- one carbon atom is replaced by a carbonyl or S(O)_m; and

- one to four carbon atoms may optionally be replaced by oxygen,
nitrogen or NR₃, S(O)_m, carbonyl, and
such ring may be substituted by 1 to four R₆ groups;

R₆

has the same meanings of R₅;

30

Y

is nitrogen or -CR₇;

R₇

hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;

X

is carbon or nitrogen;

m


is 0, 1 or 2;

n

is 1 or 2.


35

2. Compounds according to claim 1, in which W is selected among the following groups:




3. Compounds of formula (IIIa), according to claims 1-2, in which Z corresponds to a pyrazole derivative, R₇ is hydrogen and R, R₁, R₅, and W have the meanings defined in claims 1-2.

5



4. A process for preparing the compounds of formula (IIIa) according to claim 3, comprising the following steps:



10

step a stands for the formation of the pyrrolidinone moiety of compounds (VI), which will form the cycle B present in the final compounds (IIIa), by reacting the compounds (V) with a reactive derivative of the butyric acid, followed by a cyclisation reaction in basic conditions;

15 step b stands for amidine formation by reacting the compounds (VI) with 3-aminocrotonate and POCl₃;

step c stands for the cyclisation of the compounds (VII) in basic conditions to give the pyridinone precursor of cycle A in the final compounds (IIIa);
step d stands for the formation of a reactive derivative of the pyridinone of compounds (VIII);
5 step e stands for nucleophilic displacement of the leaving group of compounds (IX) to give the iodinated compounds (X);
step f stands for the arylation reaction with the suitable pyrazole derivative by a metal catalysed coupling reaction procedure to give the final compounds (IIIa).

10 5. The use of a compound according to claim 1, in the preparation of a medicament for use in the treatment of conditions mediated by CRF (corticotropin-releasing factor).

15 6. The use of a compound according to claim 1, in the preparation of a medicament for use in the treatment of depression and anxiety.


7. The use of a compound according to claim 1, in the preparation of a medicament for use in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease).

20 8. A compound according to claim 1, for use in the treatment of conditions mediated by CRF (corticotropin-releasing factor).

25 9. A pharmaceutical composition comprising a compound of claim 1, in admixture with one or more physiologically acceptable carriers or excipients.

Abstract

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof




5

wherein

- R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups
- G selected from:
halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, -NR₃R₄, cyano, and a group W;
- R₁ is hydrogen, C1-C6 alkyl, C1-C6 alkoxy; C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano;
- R₂ is a C1-C4 alkyl, -OR₃ or -NR₃R₄;
- R₃ is hydrogen or C1-C6 alkyl;
- R₄ is hydrogen or C1-C6 alkyl;
- Z is a 5-6 membered heterocycle, which may be substituted by 1 to 4 R₅ groups;
- R₅ is a C1-C6 alkyl, halo C1-C2 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;
- W is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and
in which:
 - one carbon atom is replaced by a carbonyl or S(O)_m; and
 - one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR₃, S(O)_m, carbonyl, and
such ring may be substituted by 1 to four R₆ groups;
- R₆ has the same meanings of R₅;
- Y is nitrogen or -CR₇;
- R₇ hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;
- X is carbon or nitrogen;
- m is 0, 1 or 2;
- n is 1 or 2;

35 to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).

PCT/IB2001/001350



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox